B.J. Monk

525 citations

57 papers · 367 indexed · h-index 11

Impact in

Reproductive Medicine top 5%
- Ovarian cancer diagnosis and treatment
Obstetrics and Gynecology top 5%
- Endometrial and Cervical Cancer Treatments

Papers in ⓘ

Reproductive Medicine 31
- Ovarian cancer diagnosis and treatment 31
Obstetrics and Gynecology 23
- Endometrial and Cervical Cancer Treatments 23

Co-authors: S. Diane Yamada (1 shared paper)Trilok Parekh (8 shared papers)Andrés Poveda (6 shared papers)Antonio Nieto (4 shared papers)Stuart Kaye (3 shared papers)Michael W. Sill (4 shared papers)Prafull Ghatage (2 shared papers)Moni Roy (2 shared papers)
Journals: Annals of Oncology (13 papers)Gynecologic Oncology (11 papers)Journal of Clinical Oncology (10 papers)International Journal of Gynecological Cancer (2 papers)ESMO Open (2 papers)
Partner nations: United States Spain Italy

In The Last Decade

B.J. Monk

54 papers receiving 355 citations

Peers

Countries citing papers authored by B.J. Monk

Since Specialization

Citations

This map shows the geographic impact of B.J. Monk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B.J. Monk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B.J. Monk more than expected).

Fields of papers citing papers by B.J. Monk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B.J. Monk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B.J. Monk. The network helps show where B.J. Monk may publish in the future.

Co-authors

The 25 scholars most cited alongside B.J. Monk, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with B.J. Monk Line = papers co-authored together B.J. Monk links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 57 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study Annals of Oncology ·B.J. Monk, Prafull Ghatage, Trilok Parekh, Erin D. Henitz, Roland E. Knoblauch, A. Soto Matos-Pita, Antonio Nieto, Y.C. Park, P. S. Cheng., W. Li, Reyna Favis, Deborah Ricci, Andrés Poveda	2015	53
2	Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Annals of Oncology ·Stuart Kaye, Nicoletta Colombo, B.J. Monk, Sergei Tjulandin, Beihua Kong, Moni Roy, Stephen Chan, Emilia Filipczyk−Cisarż, Hans Hagberg, Ignace Vergote, Claudia Lebedinsky, Trilok Parekh, P. Santabárbara, Y C Park, Antonio Nieto, Andrés Poveda	2010	47
3	Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study Yearbook of Obstetrics Gynecology and Women s Health ·S. Diane Yamada, B.J. Monk	2006	24
4	Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO) Gynecologic Oncology ·Bhavana Pothuri, Stephanie V. Blank, Tashanna Myers, Jeffrey F. Hines, Leslie M. Randall, Roisin E. O’Cearbhaill, Brian M. Slomovitz, Ramez N. Eskander, Angeles Alvarez Secord, Robert L. Coleman, Joan L. Walker, B.J. Monk, Kathleen N. Moore, David M. O’Malley, Larry J. Copeland, Thomas J. Herzog	2023	20
5	LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study Annals of Oncology ·Robert L. Coleman, Domenica Lorusso, Christine Gennigens, Antonio González-Martı́n, L. Randall, David Cibula, Bente Lund, Linn Woelber, Sandro Pignata, Frédéric Forget, A. Redondo, Reshma Rangwala, Signe Diness Vindeløv, M. Chen, Jeffrey R. Harris, Leonardo Nicacio, M. Teng, M.R. Smith, B.J. Monk, I. Vergote	2020	17
6	530P PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety Annals of Oncology ·Andrew Martin, Bhavana Pothuri, I. Vergote, W. Graybill, Mansoor R. Mirza, C. Mccormick, D. Lorusso, Gilles Freyer, Floor Backes, Klaus Baumann, Andrés Redondo, R. G. Moore, Christof Vulsteke, R.E. O’Cearbhaill, Izabela Malinowska, L. Shtessel, Natalie Compton, B.J. Monk	2022	16
7	A randomized phase III trial of four cisplatin (CIS) containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a gynecologic oncology group (GOG) study. Journal of Clinical Oncology ·B.J. Monk, Michael W. Sill, D. Scott McMeekin, David E. Cohn, Lois M. Ramondetta, Cecelia H. Boardman, J Bénda	2008	15
8	Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer. Journal of Clinical Oncology ·B.J. Monk, T.J. Herzog, Stuart Kaye, Carolyn Krasner, J. B. Vermorken, Franco M. Muggia, Eric Pujade-Lourraine, P. Zintl, Trilok Parekh, Andrés Poveda	2011	14
9	A randomized phase II study: Pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L+P) in advanced and recurrent cervical cancer (CC) Journal of Clinical Oncology ·B.J. Monk, Luís Más, J. J. Zarba, Ana Oaknin, Carole Tarpin, Wichai Termrungruanglert, Jacquelyn A. Alber, Jian Ding, N. W. Stutts, Lini Pandite	2009	11
10	Final Overall Survival Analysis of the Phase III Randomized Trial of Chemotherapy with and Without Bevacizumab for Advanced Cervical Cancer: a Nrg Oncology - Gynecologic Oncology Group Study Annals of Oncology ·Krishnansu S. Tewari, Michael W. Sill, Richard T. Penson, Helen Huang, Lois M. Ramondetta, Lisa M. Landrum, Ana Oaknin, Thomas Reid, Mario M. Leitão, B.J. Monk, H.E. Michael	2014	11
11	POLYMORPHISM OF THE HPV-16 E6 GENE OF CERVICAL-CARCINOMA International Journal of Oncology ·R. A. Burger, Alvarez-Salas Lm, S P Wilczynski, B.J. Monk, JA DIPAOLO	1995	10
12	Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr+PLD) versus PLD alone: Results from a PPS cohort of a phase III study. Journal of Clinical Oncology ·A. Poveda, S. Tjulandin, Beihua Kong, Moni Roy, Siew Wui Chan, Emilia Filipczyk−Cisarż, H Hagberg, Claudia Lebedinsky, Trilok Parekh, B.J. Monk	2010	10
13	FDG-PET for Management of Cervical and Ovarian Cancer Yearbook of Obstetrics Gynecology and Women s Health ·B.J. Monk	2006	9
14	VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer Annals of Oncology ·I. Vergote, Alejandro Pérez Fidalgo, E.P. Hamilton, Giorgio Valabrega, Toon Van Gorp, J. Sehouli, David Cibula, Tomer Levy, Stephen Welch, Debra L. Richardson, Eva María Guerra Alia, Giovanni Scambia, Sabine Henry, Pauline Wimberger, Danielle Miller, José Gil Martínez, B.J. Monk, Sharon Shacham, Mansoor Raza Mirza, V. Makker	2022	8
15	8028 Safety analysis of trabectedin in combination with pegylated liposomal doxorubicin (PLD) vs PLD alone in ovarian cancer patients 65 years of age and older European Journal of Cancer Supplements ·I. Vergote, Jan B. Vermorken, Éric Pujade-Lauraine, B.J. Monk, Alla Lisyanskaya, Janusz Rolski, S. Vasanthan, P. Santabárbara, Eliel Bayever, Andrés Poveda	2009	7
16	1 Avelumab in combination with and/or following chemotherapy vs chemotherapy in treatment-naive patients with ovarian cancer: biomarker analyses from the phase 3 JAVELIN Ovarian 100 trial Jonathan A. Ledermann, Nicoletta Colombo, Amit M. Oza, Keiichi Fujiwara, MJ Birrer, Leslie M. Randall, Elena Poddubskaya, Giovanni Scambia, Y. Shparyk, Mei Chin Lim, Joohyuk Sohn, Kan Yonemori, R. I. Stewart, Xiao‐Ou Zhang, Julia Perkins Smith, Carlos Linn, B.J. Monk	2020	5
17	Prognostic significance of ethnicity and age in advanced stage ovarian cancer: An analysis of GOG 218 Gynecologic Oncology ·Nefertiti C. duPont, Mark F. Brady, Robert A. Burger, B.J. Monk	2013	5
18	Quality-of-life results of a randomized phase III trial of four cisplatin (Cis) containing doublet combinations in stage IVB cervical carcinoma: A gynecologic oncology group (GOG) study Journal of Clinical Oncology ·Lari Wenzel, Huaiyi Huang, David Cella, B.J. Monk, M. W. Sill, Scott McMeekin, David E. Cohn, Lois M. Ramondetta, Cecelia H. Boardman, J Bénda	2008	5
19	A phase II evaluation of sunitinib (SU11248) in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG) study Gynecologic Oncology ·John K. Chan, William E. Brady, Jubilee Brown, Mark S. Shahin, P.G. Rose, Jee Hung Kim, Angeles Alvarez Secord, Joan L. Walker, B.J. Monk	2015	5
20	LBA2 Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study Annals of Oncology ·Nicoletta Colombo, Coraline Dubot, Domenica Lorusso, Valeria Cáceres, Kosei Hasegawa, Ronnie Shapira‐Frommer, Krishnansu S. Tewari, Pamela Salman, Eduardo Aguayo de Hoyos, Eduardo Yáñez, (unknown), Mivael Olivera, Vanessa Samouëlian, Vincent Castonguay, A. Arkhipov, S. Toker, Ka Wan Li, Stephen J. O’Keefe, B.J. Monk	2021	4

About B.J. Monk

B.J. Monk is a scholar working on Reproductive Medicine, Obstetrics and Gynecology, Pulmonary and Respiratory Medicine, Oncology and Epidemiology, having authored 57 papers that have together received 367 indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (31 papers), Endometrial and Cervical Cancer Treatments (23 papers), Cervical Cancer and HPV Research (9 papers), PARP inhibition in cancer therapy (5 papers), Renal cell carcinoma treatment (5 papers), Cancer Immunotherapy and Biomarkers (5 papers), Sarcoma Diagnosis and Treatment (5 papers) and Lung Cancer Treatments and Mutations (5 papers). The work is most often cited by research in Reproductive Medicine (191 citations), Obstetrics and Gynecology (135 citations), Oncology (135 citations), Cancer Research (48 citations) and Pathology and Forensic Medicine (44 citations). B.J. Monk has collaborated with scholars based in United States, Spain and Italy. Frequent co-authors include S. Diane Yamada, Trilok Parekh, Andrés Poveda, Antonio Nieto, Stuart Kaye, Michael W. Sill, Prafull Ghatage, Moni Roy, Deborah Ricci and Roland E. Knoblauch. Their work appears in journals such as Annals of Oncology, Gynecologic Oncology, Journal of Clinical Oncology, International Journal of Gynecological Cancer and ESMO Open.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact